1.
|
19 p, 7.5 MB |
Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab
/
Granell-Geli, Júlia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Izquierdo-Gracia, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sellés-Rius, Ares (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Teniente Serra, Aina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Presas-Rodríguez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mansilla Lopez, Maria Jose (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Brieva Ruiz, L (Hospital Universitari Arnau de Vilanova) ;
Sotoca Fernández, Javier (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Mañé-Martínez, María Alba (Hospital Universitari Joan XXIII de Tarragona) ;
Moral, Ester (Hospital de Sant Joan Despí Moisès Broggi) ;
Bragado, Irene (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Goelz, Susan (Biogen Idec) ;
Martínez Cáceres, Eva María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Natalizumab is a monoclonal antibody that binds CD49d. Although it is one of the most effective treatments for Relapsing-Remitting Multiple Sclerosis (RRMS), a dosing regimen has not been optimized for safety and efficacy in individual patients. [...]
2021 - 10.3390/jpm11121347
Journal of Personalized Medicine, Vol. 11 (december 2021)
|
|
2.
|
19 p, 7.0 MB |
Exposing and Overcoming Limitations of Clinical Laboratory Tests in COVID-19 by Adding Immunological Parameters; A Retrospective Cohort Analysis and Pilot Study
/
Sánchez-Montalvá, Adrián (Hospital Universitari Vall d'Hebron) ;
Álvarez-Sierra, Daniel (Hospital Universitari Vall d'Hebron) ;
Martínez Gallo, Mónica (Hospital Universitari Vall d'Hebron) ;
Perurena-Prieto, Janire (Hospital Universitari Vall d'Hebron) ;
Arrese-Muñoz, Iria (Hospital Universitari Vall d'Hebron) ;
Ruiz-Rodriguez, Juan Carlos (Hospital Universitari Vall d'Hebron) ;
Espinosa-Pereiro, Juan (Hospital Universitari Vall d'Hebron) ;
Bosch-Nicolau, Pau (Hospital Universitari Vall d'Hebron) ;
Martínez Gómez, Xavier (Hospital Universitari Vall d'Hebron) ;
Antón, Andrés (Hospital Universitari Vall d'Hebron) ;
Martínez-Valle, Ferran (Hospital Universitari Vall d'Hebron) ;
Riveiro Barciela, Mar (Hospital Universitari Vall d'Hebron) ;
Blanco-Grau, Albert (Hospital Universitari Vall d'Hebron) ;
Rodríguez Frías, Francisco (Hospital Universitari Vall d'Hebron) ;
Castellano-Escuder, Pol (Universitat de Barcelona) ;
Poyatos Cantón, E (Hospital Universitari de Bellvitge) ;
Bas, Jordi (Hospital Universitari de Bellvitge) ;
Martínez Cáceres, Eva María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sánchez, Alex (Hospital Universitari Vall d'Hebron) ;
Zurera Egea, Coral (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Teniente Serra, Aina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Hernández-González, Manuel (Hospital Universitari Vall d'Hebron) ;
Pujol-Borrell, Ricardo (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Two years since the onset of the COVID-19 pandemic no predictive algorithm has been generally adopted for clinical management and in most algorithms the contribution of laboratory variables is limited. [...]
2022 - 10.3389/fimmu.2022.902837
Frontiers in immunology, Vol. 13 (june 2022)
|
|
3.
|
18 p, 2.5 MB |
Transfection of Vitamin D3-Induced Tolerogenic Dendritic Cells for the Silencing of Potential Tolerogenic Genes. Identification of CSF1R-CSF1 Signaling as a Glycolytic Regulator
/
Mansilla Lopez, Maria Jose (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
González-Larreategui, Íñigo (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Figa-Martín, Neus (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Barallat, Jaume (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Fondelli, Federico (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Sellés-Rius, Ares (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Quirant, Bibiana (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Teniente Serra, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Martínez Cáceres, Eva María (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
The use of autologous tolerogenic dendritic cells (tolDC) has become a promising strategy to re-establish immune tolerance in autoimmune diseases. Among the different strategies available, the use of vitamin D3 for the generation of tolDC (VitD3-tolDC) has been widely tested because of their immune regulatory properties. [...]
2021 - 10.3390/ijms22147363
International journal of molecular sciences, Vol. 22, Num. 14 (July 2021) , art. 7363
|
|
4.
|
12 p, 656.3 KB |
Immunological parameters as biomarkers of response to MicroCrystalline Tyrosine-adjuvanted mite immunotherapy
/
Justicia, José L. (Allergy Therapeutics Ibérica (Barcelona)) ;
Padró, Clara (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Roger, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Moreno, Francisco (Dr. Lobatón Clinic (Càdis)) ;
Rial, Manuel J. (Complejo Hospitalario Universitario de A Coruña) ;
Parra, Antonio (Complejo Hospitalario Universitario de A Coruña) ;
Valero, Antonio (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Malet, Alfonso (Al·lergo Centre (Barcelona, Catalunya)) ;
Teniente Serra, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Boronat, Anna (Allergy Therapeutics Ibérica (Barcelona)) ;
Torán-Barona, Carla (Allergy Therapeutics Ibérica (Barcelona))
Despite the effectiveness of allergen immunotherapy (AIT), some patients are unresponsive for reasons still unknown; yet validated response biomarkers remain unavailable. To analyze immunological parameters as biomarkers to monitor and predict clinical response to a MicroCrystalline Tyrosine-adjuvanted house dust mite (HDM) AIT in patients with allergic rhinitis (AR). [...]
2021 - 10.1016/j.waojou.2021.100545
The World Allergy Organization Journal, Vol. 14 (june 2021)
|
|
5.
|
13 p, 3.3 MB |
Comparative transcriptomic profile of tolerogenic dendritic cells differentiated with vitamin D3, dexamethasone and rapamycin
/
Navarro-Barriuso, Juan (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Mansilla Lopez, Maria Jose (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Naranjo-Gómez, Mar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sánchez, Alex (Universitat de Barcelona. Departament d'Estadística) ;
Quirant, Bibiana (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Teniente Serra, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Cáceres, Eva María (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Tolerogenic dendritic cell (tolDC)-based therapies have become a promising approach for the treatment of autoimmune diseases by their potential ability to restore immune tolerance in an antigen-specific manner. [...]
2018 - 10.1038/s41598-018-33248-7
Scientific reports, Vol. 8 (october 2018)
|
|
6.
|
14 p, 1.8 MB |
NK Cell Subsets Changes in Partial Remission and Early Stages of Pediatric Type 1 Diabetes
/
Gómez Muñoz, Laia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Perna-Barrull, David (Institut Germans Trias i Pujol) ;
Villalba Felipe, Adrián (Institut Germans Trias i Pujol) ;
Rodríguez-Fernández, Silvia (Institut Germans Trias i Pujol) ;
Ampudia Carrasco, Rosa María (Institut Germans Trias i Pujol) ;
Teniente Serra, Aina (Institut Germans Trias i Pujol) ;
Vazquez, Federico (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Murillo-Vallés, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Pérez Sánchez, Jacobo (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Corripio, Raquel (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ;
Bel, Joan (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Vives Pi, Marta (Institut Germans Trias i Pujol)
Type 1 diabetes (T1D) is a chronic metabolic disease characterized by the autoimmune destruction of β-cells in the pancreatic islets. T1D is preceded by islet-specific inflammation led by several immune cells. [...]
2021 - 10.3389/fimmu.2020.611522
Frontiers in immunology, Vol. 11, art. 611522 (january 2021)
|
|
7.
|
14 p, 1.3 MB |
Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4 + Cells Towards a Functional Hyporesponsiveness
/
Navarro-Barriuso, Juan (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Mansilla Lopez, Maria Jose (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Quirant, Bibiana (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Teniente Serra, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez-Cáceres, Eva M. (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
The use of autologous tolerogenic dendritic cells (tolDC) has become a promising alternative for the treatment of autoimmune diseases. Among the different strategies available, the use of vitamin D3 for the generation of tolDC (vitD3-tolDC) constitutes one of the most robust approaches due to their immune regulatory properties, which are currently being tested in clinical trials. [...]
2021 - 10.3389/fimmu.2020.599623
Frontiers in immunology, Vol. 11 (january 2021)
|
|
8.
|
|
9.
|
22 p, 2.2 MB |
Paving the way towards an effective treatment for multiple sclerosis : advances in cell therapy
/
Mansilla Lopez, Maria Jose (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Presas Rodríguez, Sílvia (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Teniente Serra, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
González-Larreategui, Íñigo (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Quirant, Bibiana (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Fondelli, Federico (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Djedovic, Neda (University of Belgrade. Department of Immunology) ;
Iwaszkiewicz-Grzes, Dorota (Poltreg S.A., Gdańsk, Poland) ;
Chwojnicki, K. (Medical University of Gdańsk. Department of Anaesthesiology & Intensive Care) ;
Miljković, Đ. (University of Belgrade. Department of Immunology) ;
Trzonkowski, P. (Poltreg S.A., Gdańsk, Poland) ;
Ramo-Tello, Cristina (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Martínez Cáceres, Eva María (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Multiple sclerosis (MS) is a leading cause of chronic neurological disability in young to middle-aged adults, affecting ~2. 5 million people worldwide. Currently, most therapeutics for MS are systemic immunosuppressive or immunomodulatory drugs, but these drugs are unable to halt or reverse the disease and have the potential to cause serious adverse events. [...]
2021 - 10.1038/s41423-020-00618-z
Cellular and Molecular Immunology, Vol. 18 (may 2021) , p. 1353-1374
|
|
10.
|
11 p, 2.0 MB |
Optimal response to dimethyl fumarate is mediated by a reduction of Th1-like Th17 cells after 3 months of treatment
/
Mansilla Lopez, Maria Jose (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Navarro-Barriuso, Juan (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Presas-Rodríguez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Teniente Serra, Aina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Quirant, Bibiana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ramo-Tello, Cristina (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Martínez Cáceres, Eva María (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Dimethyl fumarate (DMF) is one of the most promising therapies for relapsing-remitting multiple sclerosis (RRMS) patients since it has shown immunomodulatory and neuroprotective effects. However, a percentage of RRMS patients do not exhibit an optimal response to DMF. [...]
2019 - 10.1111/cns.13142
CNS neuroscience & therapeutics, Vol. 25 (2019) , p. 995-1005
|
|